Novavax revenue plunges 79% as company pivots to licensing-led model
Novavax (NASDAQ:NVAX) reported a significant contraction in top-line results for the first quarter of 2026, reflecting the company’s ongoing transition from a high-volume manufacturer to a leaner, research-and-licensing-focused biotechnology entity.











